anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Early in life, individuals with Rett syndrome lose purposeful use of their hands and engage in handwringing and handmouthing stereotypies. It is important to pursue interventions that may facilitate the development and sustained use of arms/hands for productive involvement in daily needs that ultimately improve quality of life. Investigators plan to use a tele-research approach to assist caregivers and the participants in playing customized computer generated games that require independent and sustained hand separations and initiated and sustained movement patterns to control the modified virtual reality activity that serves as our intervention. Customization of the games and activities used will require collaboration with the caregivers of each participant to ensure that the level of motivation and interest of the participant matches the game/activities used. Brightly colored wristbands will be worn on each participant's wrist during the one-hour long intervention in which they will be involved 3 days per week for \~12 weeks. These wrist bands will be detected by the software we developed. As the participants move their arms, our software will detect these position changes and activate the computer-based activities. At 5 different points in the study investigators will test for changes in independent reaching abilities that may result from exposure to the intervention. Specifically, investigators will assess the impact of the intervention on minimizing hand stereotypies and improving the amount and quality of independent arm function. At the start and end of the study, investigators will also assess the impact the intervention had on activities of daily living, and therefore quality of life, via three goals developed in collaboration with the family/caregiver of the participant. Due to the virtual nature (tele-research) of the study, investigators aim to recruit 10-12 participants from multiple countries. Once enrolled, each participant will remain involved for up to 5-6 months. Since all activities are hand selected for each participant in collaboration with the caregivers, risks of involvement in this study are low. Investigators anticipate that this intervention will improve motor planning abilities for arm use and reduce stereotypies.
The present invention discloses a medicine prepared from longestapex beautyberry root, which has the functions of expelling wind, dredging channels and relieving pain. The medicine is composed of longThe invention discloses a wind-dispelling meridian-dredging pain-stopping Callicarpa longissima (Hemsl.)Merr medicine, prepared of Callicarpa longissima (Hemsl.)Merr, Radix Aconiti Brachypodi, calabasestapex beautyberry root, shortstalk monkshood root, easter heraldtrumpet root or leaf, trifoliate acanthopanax root or root-bark, lanceolate jasmine root or stem, radde anemone rhizome, Chinese starjh, Acanthopanax trifoliatus (L.)Merr, Lonicera standishii Jacques, Radde Anemone Rhizome, Chinese Starjasmine Stem, Lethariella Zahlbruckneri, Vaccinium dunalianum wight var.urophyllum Rehd.et Wils, Aasmine stem, green alectoria filament, south China blueberry, shaggy ardisia, walking spleenwort, oblongleaf kadsura stem or root, coninshaped blueberry branchlet and leaf, Chinese tupistra and ethanordisia villosa Roxb, Asplenium prolongatum Hook, Kadsura oblongifolia Merr, Cheng Blueberry Twig and Leaf, Disporopsis longifolia Craib, and alcohol (concentration 35-75%) in a certain weight proportil (the concentration is from 35 to 75%) according to a certain weight proportion. By the combination, the effects of the traditional Chinese herbs are integrated into a synergistic function, so that ton; these drugs cooperate to be able to have reliable curative effect on rheumatic arthrosis, traumatic injury, traumatic hemorrhage, physique pains, rheumatic physique pains, rheumatic arthritis, sofhe medicine has the exact effects of effectively treating rheumatism arthralgia, traumatic pain, traumatic injury, trauma breeding, sprain pain of the tendons and bones, tendon and bone pain, trauma st tissue injury, etc; and it is an ideal specific medicine for curing traumatic injury and rheumatic joint diseases.                                                                                    tasis pain, rheumatism tendon and bone pain, rheumarthritis and soft tissue contusion. Thereby, the medicine is an ideal specific medicine for treating traumatic injury and rheumatism joint diseases.
The investigators will conduct a phase II factorial clinical trial . The clinical trial will determine the benefit of prescribed low-intensity physical activity, behavioral management, or both, versus standard rest in acute (24-48 hrs) (Moderate Traumatic Brain Injury (mTBI) patients presenting to the pediatric Emergency Department (ED). Low-intensity physical activity (i.e.10,000 steps/day) will be prescribed and monitored in the first week post-injury with an actigraph (Fitbit®). Behavioral management will be prescribed using a phone app referred to as mHealth (mobile Health, specifically SuperBetter©) that promotes mental, physical, social, and emotional resilience. This randomized clinical trial will have four treatment groups: 1) activity, 2) mHealth, 3) activity+mHealth, 4) rest. The primary study outcomes will be symptoms and recovery by 14 days. All subjects will be assessed via phone at 3-5 days and in person at 14 days. The secondary outcomes will be to determine the influence of interventions on comprehensive aspects of physiologic recovery and patient-centered outcomes; including symptoms at 3 days, neurocognitive, vestibular/ocular motor impairment at 14 days, pediatric quality of life measures, time to symptom resolution, and return to normal activity via phone survey at 1 and 2 months. The investigators will assess symptom, quality of life, and recovery outcomes based on treatment group assignment for all subjects and high-risk subjects.
The present technology provides for a cell-synthesized biological particle, the processes for making a cell-synthesized particle, and a process for assembling such cell-synthesized particles into tissues and organs. The particles are synthesized in culture in vitro by living cells that produce natural extracellular matrix. Multiple particles can be assembled into tissues that have significant void space. The particles or tissues can act as a substrate for additional cell types. The particles or tissues can be further cultured in vitro to achieve favorable cell or extracellular matrix growth, organization or other desired characteristics. The particles or tissues can be devitalized or decellularized. The particles or tissues can be injected or implanted in a human to repair, enhance, or create a secretory, mechanical, or aesthetic function.
Tolterodine tartrate extended-release capsules contain tolterodine tartrate. The active moiety, tolterodine, is a muscarinic receptor antagonist. The chemical name of tolterodine tartrate is (R)-N, N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropanamine L-hydrogen tartrate. The empirical formula of tolterodine tartrate is C26H37NO7. Its structure is:

Tolterodine tartrate is a white, crystalline powder with a molecular weight of 475.6. The pKa value is 9.87 and the solubility in water is 12 mg/mL. It is soluble in methanol, slightly soluble in ethanol, and practically insoluble in toluene. The partition coefficient (Log D) between n-octanol and water is 1.83 at pH 7.3.

Tolterodine tartrate extended-release capsules 4 mg capsule for oral administration contains 4 mg of tolterodine tartrate. Inactive ingredients are sucrose, starch, hypromellose, ethylcellulose, medium chain triglycerides, oleic acid, gelatin, and FD&C Blue #2.

Tolterodine tartrate extended-release capsules 2 mg capsule for oral administration contains 2 mg of tolterodine tartrate, and the following inactive ingredients: sucrose, starch, hypromellose, ethylcellulose, medium chain triglycerides, oleic acid, gelatin, yellow iron oxide, and FD&C Blue #2.

Both the 2 mg and 4 mg capsule strengths are imprinted with a pharmaceutical grade printing ink that contains shellac glaze, titanium dioxide, propylene glycol, and simethicone.
PURPOSE:To obtain a new compound useful as a psychotropic medicine having antagonism on both of a dopamine D2 receptor and a serotonin S3 receptor and thereby exhibiting excellent treating effect also on a negative symptom of schizophrenia. CONSTITUTION:A compound of formula I (R<1> is H, a cycloalkyl, etc.; R<2> is phenyl or a heteroaryl; R<2> is H or a lower alkyl; m is 2 or 3; n is 3-7) or its salts, e.g. 4-(4-ethyl-l-piperazinyl)-2-(4-fluorophenyl)-6,7,8,9-tetrahydro-5H- cyclohepta[b]pyridine. The compound is obtained by reacting, e.g. a compound of formula II with a compound of the formula R<2> COOY (Y is a lower alkyl), reacting the resultant compound with ammonia gas, converting the product into a compound of formula III (X is an eliminating atom or an eliminating group) by phosphorus tribromide and reacting the compound of formula III with a compound of formula IV at 40-200 deg.C in the presence of a base such as sodium carbonate.
Naturally menopausal women with hypoactive sexual desire disorder (HSDD) were randomized into a 52-week, multicenter, double-blind (DB), parallel-group, placebo-controlled study. Patients were stratified based on presence/absence of uterus and randomized to receive placebo or testosterone transdermal system. Patients had to maintain a stable dose of estrogen/progestin throughout the study. Patients who completed the first 52 weeks of the study were given the opportunity to participate in year 2-4 open-label (active treatment) study extension which was added to the protocol by amendment. Safety was assessed by adverse events, lipids, serum chemistry with hepatic, renal and carbohydrate metabois in evaluation, coagulation testing, and hermatology. Physical exam including clinical assessments of facial hair and acne were monitored.
The invention provides a method of inhibiting surface-induced nuclear spin relaxation and surface trapping of a hyperpolarized noble gas, most preferably 129Xe, by polymercoated surfaces. The method includes inhibiting the amount of interaction of the noble gas with a polymeric coating on the surface of apparatus which contacts the noble gas.  Preferably, the method includes inhibiting noble gas nuclear spin relaxation by replacing at least some of the protons in the polymer with substituents which have non-zero nuclear spin and/or reduced polymer permeability. A preferred substituent having non-zero spin is deuterium. A preferred modification which reduces permeability includes introducing into the polymer a substituent such as a halogen, more preferably fluorine. The method also provides containers having surfaces which have been coated with a polymer which inhibits noble gas trapping and nuclear spin relaxation. Furthermore, the invention provides methods for enhancing the production and storage of a hyperpolarized noble gas by decreasing the relaxation of nuclear spin and limiting the trapping of the noble gas in a polymeric coating of apparatus containing the noble gas.
Bovine respiratory disease (BRD) complex, shipping fever, or pneumomic pasteurellosis, is a multifactorial disease whereby a combination of viral infection, adverse environment and poor immune status may combine to predispose animals to bacterial infections. The exotoxin, or leukotoxin (Lkt), may contribute to pathogenesis by impairing the primary lung defenses and subsequent immune responses or by causing inflammations as a result of leukocyte lysis. The present invention provides a modified microorganism which produces an Lkt toxin, wherein said Lkt toxin is partially or fully inactivated. In a further embodiment of the present invention, there is provided a modified microorganism wherein an Lkt toxin operon including an Lkt structural gene and/or a post transational activator of the organism is partially or fully inactivated. The present applicants have found that a precursor of Lkt toxin has reduced toxic activity. Surprisingly, the Lkt toxin precursor is capable of inducing an immune response in an animal that offers cross protection against heterologous challenge with a microorganism which produces the Lkt toxin. A microorganism which naturally produces an Lkt toxin may be engineered to produce an inactive Lkt toxin precursor by eliminating the post-translational activator of the precursor product. Accordingly, in a preferred embodiment the microorganism is unable to produce a post-translational activator of the Lkt toxin precursor or produces an inactivated post-translational activator of the Lkt toxin precursor. The post-translational activator may be a product of the Lkt C gene.
BACKGROUND: Surgical left atrial appendage (LAA) closure concomitant to open-heart surgery prevents thromboembolism in high-risk patients. Nevertheless, high-level evidence does not exist for LAA closure performed in patients with any CHA2DS2-VASc score and preoperative atrial fibrillation or flutter (AF) status-the current trial attempts to provide such evidence.
METHODS: The study is designed as a randomized, open-label, blinded outcome assessor, multicenter trial of adult patients undergoing first-time elective open-heart surgery. Patients with and without AF and any CHA2DS2-VASc score will be enrolled. The primary exclusion criteria are planned LAA closure, planned AF ablation, or ongoing endocarditis. Before randomization, a three-step stratification process will sort patients by site, surgery type, and preoperative or expected oral anticoagulation treatment. Patients will undergo balanced randomization (1:1) to LAA closure on top of the planned cardiac surgery or standard care. Block sizes vary from 8 to 16. Neurologists blinded to randomization will adjudicate the primary outcome of stroke, including transient ischemic attack (TIA). The secondary outcomes include a composite outcome of stroke, including TIA, and silent cerebral infarcts, an outcome of ischemic stroke, including TIA, and a composite outcome of stroke and all-cause mortality. LAA closure is expected to provide a 60% relative risk reduction. In total, 1500 patients will be randomized and followed for 2 years.
DISCUSSION: The trial is expected to help form future guidelines within surgical LAA closure. This statistical analysis plan ensures transparency of analyses and limits potential reporting biases.
TRIAL REGISTRATION: Clinicaltrials.gov, NCT03724318. Registered 26 October 2018, https://clinicaltrials.gov/study/NCT03724318 .
PROTOCOL VERSION: https://doi.org/10.1016/j.ahj.2023.06.003 .
BACKGROUND/AIMS: To present a case series of patients with facial nerve palsy (FNP) undergoing lower eyelid surgery where inadequate horizontal tarsal length was encountered and managed with a periosteal flap.
METHODS: A two-centre retrospective, non-comparative case series of all patients with FNP who underwent lower eyelid periosteal flap procedures. Theatre records identified all such procedures performed by, or under the supervision of, one of two surgeons (RM, BCP) between November 2018 and November 2020. Outcome measures, including the Cornea, static Asymmetry, Dynamic function, Synkinesis grading score, were measured preoperatively and postoperatively.
RESULTS: All 17 patients had undergone medial canthal tendon (MCT) plication. Six had previously undergone MCT plication then were listed for further lower eyelid surgery. In 11 cases, horizontal deficiency was encountered intraoperatively, immediately following MCT plication. Four patients were surgery-naïve. 94% were within the 'contraction phase' of FNP (ie, greater than 1-year duration); eight (45%) had previously undergone lower eyelid shortening procedures (such as lateral tarsal strip procedure, LTS). All patients had improved lower eyelid position postoperatively, although at 1-year postoperation, four patients require redo lower eyelid surgery.
CONCLUSIONS: MCT plication and stabilisation appear to be closely linked to the need for lower eyelid lengthening procedures, particularly in patients who have also undergone LTS and/or those within the 'contraction phase' of FNP. Unnecessary loss of horizontal tarsal length (particularly during LTS procedures) must be avoided in patients with FNP. Surgeons managing such patients should take care to identify inadvertent eyelid shortening early and be prepared to perform a lateral periosteal flap when required.
Short-acting GnRH-a will be administered daily since the mid-luteal phase for pituitary down-regulation. 14 days after down-regulation,serum levels of follicle stimulating hormone (FSH), luteinizing hormone (LH) and E2 will be measured. Meanwhile, about 2ml of peripheral blood will be preserved for SNP analysis of the GnRH receptor genes. Once the patients are judged to achieve pituitary down-regulation, ovarian stimulation will be started. B-mode ultrasonography and determination of hormone levels will be performed regularly according to the course of follicle maturation. An appropriate dose of human menopause gonadotropin (HMG) (75\~150IU) will be added when follicles are larger than 12\~14mm in diameter. When one leading follicle is \>18mm in diameter, or two follicles are \>17mm in diameter, or three follicles are \>16mm in diameter, final ovulation will be triggered by a single injection of human chorionic gonadotropin (HCG) 4,000\~10,000 IU or Ovidrel® 250μg (equivalent to HCG 6,500IU).Oocyte retrieval guided by vaginal ultrasonography will be conducted 35\~36 hours after HCG or Ovidrel®injection.Fertilization and embryo culture will be performed according to the standard IVF or intracytoplasmic sperm injection (ICSI) protocol.Embryo transfer and cryopreservation will be performed 3\~5 days after oocyte retrieval. Luteal support will be provided after embryo transfer according to the Center's routine practice. Serum β-HCG level will be measured 12\~14 days after embryo transfer to determine biochemical pregnancy, and transvaginal ultrasonography will be performed 4\~5 weeks after embryo transfer to determine clinical pregnancy.

For data analysis, patients will be divided into two groups according to their serum LH level on day 14 after pituitary down-regulation - one group of patients with an LH level above the median of the group and another group of patients with an LH level below the median of the group.Comparisons will be made between the two groups in the following aspects: 1) age; BMI; basal levels of LH, FSH and prolactin (PRL); serum levels of FSH, LH, E2 and progesterone on the day of HCG injection; the numbers of oocytes retrieved, the number of cleavage, the number of transferrable embryos, the number of embryos transferred and the clinical pregnancy rate; and 2) genotyping results at the 11 SNP loci of the GnRH receptor genes.
The present invention relates to a method for expressing each of peptide antibiotics P 5 3  and Anal 3 35  having amphiphilicity and showing antibacterial, antifungal and anticancer activities  61, 63, 65, 67, 69, 71,  on the microbial surface, using a vector containing outer membrane protein genes (pgsBCA) that are derived from  Bacillus  sp. strains and involved in the synthesis of poly-gamma-glutamate. Moreover, the present invention relates to lactic acid-forming bacteria having each of the peptide antibiotics P 5 15  and Anal 3 43  expressed on their surface, and the use thereof. According to the present invention, the peptide antibiotics can be expressed on the surface of various microorganisms transformed with the surface expression vectors. The inventive method for the surface expression of the peptide antibiotics allows the peptide antibiotics to be mass-produced without a purification process. Thus, the inventive method has very high industrial applicability. Further, the present invention can be applied to other peptide antibiotics besides P 5 3  and Anal 3 35.
Perioperative vision loss (POVL) is a rare but serious complication, most frequently reported after cardiac and prone spinal surgeries. POVL following lower extremity surgery is uncommon. We herein report a case of POVL in a man in his mid-thirties after a third surgery to repair a lower extremity fracture. The patient developed vision loss 3 hours postoperatively following sequential surgeries for a lower extremity fracture. Before the third surgery, he was in a hypercoagulable state, and tranexamic acid was administered to reduce intraoperative blood loss. After POVL occurred, anticoagulant and antithrombotic agents, as well as high-dose steroid pulse therapy, were promptly administered. The patient's vision recovered 3 days later, with no abnormalities found during follow-up visits over the next 6 months. For patients at high risk of thrombosis, POVL warrants careful attention. The coagulation system should be kept as stable as possible, and medications that may promote thrombosis, such as tranexamic acid, should be used cautiously.
<P>PROBLEM TO BE SOLVED: To provide an implantable medical device, which can be coated to minimize a biological organism's reaction to an introduction of the medical device to the organism.  <P>SOLUTION: The medical device can be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds are mixed with the biocompatible materials. When the therapeutic agents are delivered to a region of a disease site, liquid formulations is desirable to increase efficacy and deliverability of the particular drug. The medical device includes various stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices.  <P>COPYRIGHT: (C)2007,JPO&INPIT
The present invention provides for substituted metal chelating compounds in which at least two of the chelating atoms are nitrogen which are directly attached to aromatic rings and one or more of those nitrogen atoms has attached thereto a substituent other than hydrogen, and methods for making and using these compounds. Another aspect of the invention provides for the use of the chelation compounds described above in methods for diagnostic and therapeutic purposes. A diagnostic method is described for detecting the presence or absence of a target site within a mammalian host. This method comprises providing to cells a diagnostically effective dose of a compound of the present invention which contains a metal radionuclide, such as  99m Tc and/or  111 In, and detecting the biodistribution of the radionuclide. A therapeutic method is described for delivering a radionuclide, such as  186 Re/ 188 Re,  90 Y, and  153 Sm, to a target site within a mammalian host. This method comprises providing to cells a therapeutically effective dose of a chelate compound of the present invention.